FDA Expands Joenja Approval to Younger APDS Patients, Pharming Eyes October Launch — Pharming Group N.V.

Event summary

FDA approves Pharming’s Joenja for children aged 4–11 with APDS, expanding its existing indication.
New 40 mg and 50 mg twice-daily doses expected to launch in October 2026.
Approval based on Phase III trial showing improved immune function in pediatric patients.
Pharming also submitted a separate sNDA for lower doses for children weighing 13–27 kg.
Joenja is now the first and only FDA-approved treatment for APDS in this age group.

The big picture

Pharming’s expanded Joenja approval addresses a critical unmet need in pediatric rare disease, where diagnostic delays and progressive symptoms create high urgency for early intervention. The move reinforces the company’s focus on rare immune disorders, a segment with limited therapeutic options and strong pricing power. With APDS affecting just 1–2 people per million, Pharming’s ability to scale access and awareness will determine commercial success.

What we're watching

Market Penetration: How quickly Pharming can onboard pediatric patients and physicians into its existing distribution network.
Regulatory Momentum: Whether the FDA’s approval will accelerate reviews in other countries where Joenja is under consideration.
Competitive Positioning: The pace at which Pharming can solidify its leadership in APDS before potential rivals enter the space.